Research programme: CB5138 analogs - CohBar
Alternative Names: CB 5138-1; CB5138-2; MBT2 analogs - CohBarLatest Information Update: 28 Sep 2024
At a glance
- Originator Albert Einstein College of Medicine; University of California
- Developer CohBar
- Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Peptides; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis; Renal fibrosis; Systemic scleroderma
- No development reported Fibrosis; Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis(Prevention) in USA (Parenteral)
- 28 Jan 2024 No recent reports of development identified for preclinical development in Fibrosis in USA (Parenteral)
- 28 Jan 2024 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in USA (Parenteral)